Positive Long-Term Clinical Data on Ventus Medical's Provent Sleep Apnea Therapy Published

Twelve-Month Prospective Study Confirms Treatment Benefit, Very High Compliance

BELMONT, Calif., – Ventus Medical today announced that the results of a large, long-term study of its proprietary Provent® Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA), were published in the November 2011 issue of the Journal of Clinical Sleep Medicine, an official publication of the American Academy of Sleep Medicine.

“This study provides further validation that Provent Therapy is an effective treatment for some OSA patients as it reduces daytime sleepiness, apnea hypopnea index (AHI) and snoring associated with this prevalent condition,” said Meir Kryger, M.D., of Gaylord Sleep Medicine and past president of the American Academy of Sleep Medicine. “Patients reported wearing the device almost 90 percent of the nights, which represents very high compliance. The current gold standard, continuous positive airway pressure (CPAP) is very effective but many patients do not use it adequately. Provent represents an important new treatment option for many obstructive sleep apnea patients.”

About the Study

The 13-center, 12-month study was an extension of the 3 month study that was previously published in the Journal SLEEP. Patients who were compliant with the device and demonstrated adequate treatment were enrolled for this extension study. These patients showed a 70 percent reduction in the median AHI after 12 months of treatment with Provent Therapy. AHI is a measure of number of breathing pauses per hour of sleep. In addition, the study confirmed a very high nightly compliance rate of 89 percent. Epworth Sleepiness Scale (a measure of sleepiness) was reduced five points and snoring was reduced by 74 percent. The publication of the data can be found at: http://www.aasmnet.org/jcsm/currentissue.aspx .

“As we expand our footprint in the United States and international markets, we believe it is critically important to have solid peer-reviewed, high quality research like this study to validate the benefits of using Provent Therapy to treat OSA,” said Peter Wyles, President and Chief Executive Officer of Ventus Medical. “We commend Dr. Kryger and his colleagues on the results of this important long-term study.”

About Provent® Sleep Apnea Therapy

Provent is a proprietary medical device used for the treatment of obstructive sleep apnea (OSA). The device has been shown to be clinically effective in a series of peer-reviewed studies. It is an easy to use, non-invasive and disposable treatment that works across mild, moderate, and severe OSA. Provent Therapy utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient’s airway open during sleep and has been clinically proven in numerous studies to reduce sleep apnea. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow. During exhalation, the valve closes, limiting airflow through small openings, which increases expiratory pressure and keeps the airway open, preventing disruption in breathing. Provent® Therapy is accepted onto the Australian Register of Therapeutic Goods (ARTG), is FDA cleared and has CE marking. For more information, please visit www.proventtherapy.com

SOURCE Ventus Medical

Related Posts